CAMP — CAMP4 THERAPEUTICS CORPORATION

CAMP4 THERAPEUTICS CORPORATION (CAMP) is a biotechnology company listed on NASDAQ. It is led by Joshua Mandel-Brehm, based in One Kendall Square, Cambridge, MA, United States, 02139, with about 48 employees. Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Latest reported CAMP revenue for 2025-09-30 was $795.0K. Net income was -$15.1M. Revenue was down 46.9% from 2025-06-30 to 2025-09-30. CAMP currently screens at market cap $215.0M.

Use this CAMP page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CAMP quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CAMP SEC filings page. Lician reads the product cache first so this HTML stays unique to CAMP4 THERAPEUTICS CORPORATION even when a live quote feed is slow.